Literature DB >> 12142088

Rectum contouring variability in patients treated for prostate cancer: impact on rectum dose-volume histograms and normal tissue complication probability.

Claudio Fiorino1, Vittorio Vavassori, Giuseppe Sanguineti, Carla Bianchi, Giovanni Mauro Cattaneo, Anna Piazzolla, Cesare Cozzarini.   

Abstract

BACKGROUND: Recent investigations showed some correlation between three-dimensional (3D) treatment planning dose-volume data (dose-volume histograms: DVH, dose statistics) and rectal toxicity for patients treated for prostate cancer. However, no data are available about the possible impact of inter-institute variability in contouring the rectum, so that the possibility of reliably using information from single-centre studies remains doubtful.
PURPOSE: Within a retrospective three-institutes study on correlation between dose-volume treatment planning data and rectum bleeding in patients treated for prostate cancer, an investigation about the impact of inter- and intra-observer variability in contouring the rectum was performed.
MATERIALS AND METHODS: Ten patients were considered for a dummy run exercise and three observers (one per Institute) contoured the rectum (including filling). An anatomically based definition of rectum extension was previously accepted by the three observers. Six of the ten patients were randomly chosen in the subgroup of patients (large spacing, LS) with a distance between computed tomography (CT) slices (outside the prostate region) equal to 10 mm; for the remaining four patients the distance between CT slices was 5 mm over the whole rectum volume (small spacing, SS). The original 3D treatment planning was recovered on the Cadplan treatment planning system for each patient and rectum dose statistics (mean, median and maximum rectum dose), volume, DVH and NTCP values were calculated for each observer. For DVH analysis, the values of V(50), V(55), V(60), V(65) and V(70) (defined as the % of rectum volume receiving at least 50, 55, 60, 65, 70 Gy) were considered. Normal tissue complication probabilities (NTCPs) were calculated for the original ICRU dose and for a 75.6 Gy ICRU dose (NTCP and NTCP(75.6), respectively). Intra-observer variability was investigated by asking the observers to redraw the same rectum contours 6 months later and comparing the two contouring sessions.
RESULTS: In general, a good agreement was found for most patients and, in particular, for all SS patients. The impact of inter-observer variability was quite significant on dose statistics and DVH in two of six LS patients. Looking at the patient population, some systematic deviations, even if quite small, were demonstrated between institute B and institute C (volume, P = 0.02) and between institute A and institute B (mean/median dose, V(50)-V(65), NTCP(75.6); P < 0.05). Four of six LS patients (0/4 in the SS group) presented a maximum difference among observers at the cranial and/or caudal limit of the rectum equal to 1 cm. For these patients, inter-observer variability was significantly higher than for the others (P < 0.03). When inter-observer variability was expressed in terms of standard deviations (SD), values around 2-3 Gy and 0.5 Gy for LS and SS patients, respectively, were found for mean/median dose; values around 3-4% and 0.5-2% for LS and SS patients, respectively, were found for V(50)-V(70). The average SD for NTCP and NTCP(75.6) were 0.4 and 0.6%, respectively (0.5 and 0.9% for LS patients; 0.2 and 0.3% for SS patients). Intra-observer variability was found to be lower than inter-observer variability even if the impact on dose statistics and DVH was visible.
CONCLUSIONS: Once a robust definition of rectum is assessed, inter- and intra-institute variability in contouring the rectum appear relatively modest. However, the results suggest that the number of LS patients in DVH correlation studies should be as low as possible; the low number of these patients in the multi-centric trial involving our institutions should not have significant impact on the results of the study. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Year:  2002        PMID: 12142088     DOI: 10.1016/s0167-8140(01)00469-8

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

1.  Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.

Authors:  Pilar M Samper; M Concepción López Carrizosa; Ana Pérez Casas; Carmen Vallejo; M Carmen Rubio Rodríguez; Consuelo Pérez Vara; Miguel Melchor Iñiguez
Journal:  Clin Transl Oncol       Date:  2006-08       Impact factor: 3.405

2.  Developing and Evaluating Multimedia Patient Education Tools to Better Prepare Prostate-Cancer Patients for Radiotherapy Treatment (Randomized Study).

Authors:  Krista Dawdy; Katija Bonin; Steve Russell; Agnes Ryzynski; Tamara Harth; Christopher Townsend; Stanley Liu; William Chu; Patrick Cheung; Hans Chung; Gerard Morton; Danny Vesprini; Andrew Loblaw; Xingshan Cao; Ewa Szumacher
Journal:  J Cancer Educ       Date:  2018-06       Impact factor: 2.037

3.  A tensor-based population value decomposition to explain rectal toxicity after prostate cancer radiotherapy.

Authors:  Juan David Ospina; Frédéric Commandeur; Richard Ríos; Gaël Dréan; Juan Carlos Correa; Antoine Simon; Pascal Haigron; Renaud de Crevoisier; Oscar Acosta
Journal:  Med Image Comput Comput Assist Interv       Date:  2013

4.  Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer?

Authors:  Adam D Melancon; Jennifer C O'Daniel; Lifei Zhang; Rajat J Kudchadker; Deborah A Kuban; Andrew K Lee; Rex M Cheung; Renaud de Crevoisier; Susan L Tucker; Wayne D Newhauser; Radhe Mohan; Lei Dong
Journal:  Radiother Oncol       Date:  2007-09-24       Impact factor: 6.280

5.  Dosimetric predictors of diarrhea during radiotherapy for prostate cancer.

Authors:  Giuseppe Sanguineti; Eugene J Endres; Maria Pia Sormani; Brent C Parker
Journal:  Strahlenther Onkol       Date:  2009-06-09       Impact factor: 3.621

6.  Inter-observer variability in contouring the penile bulb on CT images for prostate cancer treatment planning.

Authors:  Lucia Perna; Cesare Cozzarini; Eleonora Maggiulli; Gianni Fellin; Tiziana Rancati; Riccardo Valdagni; Vittorio Vavassori; Sergio Villa; Claudio Fiorino
Journal:  Radiat Oncol       Date:  2011-09-24       Impact factor: 3.481

7.  Distinct effects of rectum delineation methods in 3D-conformal vs. IMRT treatment planning of prostate cancer.

Authors:  Matthias Guckenberger; Jürgen Meyer; Kurt Baier; Dirk Vordermark; Michael Flentje
Journal:  Radiat Oncol       Date:  2006-09-06       Impact factor: 3.481

8.  Monitor unit optimization in RapidArc plans for prostate cancer.

Authors:  Stefania Clemente; Mariella Cozzolino; Costanza Chiumento; Alba Fiorentino; Rocchina Caivano; Vincenzo Fusco
Journal:  J Appl Clin Med Phys       Date:  2013-05-06       Impact factor: 2.102

9.  Comparison of rectal volume definition techniques and their influence on rectal toxicity in patients with prostate cancer treated with 3D conformal radiotherapy: a dose-volume analysis.

Authors:  Cem Onal; Erkan Topkan; Esma Efe; Melek Yavuz; Serhat Sonmez; Aydin Yavuz
Journal:  Radiat Oncol       Date:  2009-05-11       Impact factor: 3.481

10.  Assessment of consistency in contouring of normal-tissue anatomic structures.

Authors:  Dawn C Collier; Stuart S C Burnett; Mayankkumar Amin; Stephen Bilton; Christopher Brooks; Amanda Ryan; Dominique Roniger; Danny Tran; George Starkschall
Journal:  J Appl Clin Med Phys       Date:  2003       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.